Partnership Opportunities in Drug Delivery Editor interviews Jarlath Keating, CEO of Phoshorex . Article entitled "CDMO Innovations to Facilitate New Therapeutics Development"
Webinar featuring our Formulation Scientist, Sydney Marchando, MS. & Nick Boylan, Ph.D., Director of Nucleic Acid Delivery.
Glioblastoma (GBM) is a malignant brain tumor that remains among the most formidable cancers.Despite a well-established standard of care of maximal surgical resection followed by radiotherapy plus concomitant temozolomide (TMZ), median survival remains approximately 15 months.